In this episode of Hospital Medicine Unplugged, we sprint through fat-soluble vitamins—A, D, E, and K—focusing on how they’re absorbed, why deficiencies happen, and the clinical syndromes hospitalists must recognize early. From intestinal transporters to neurologic deficits and neonatal bleeding, we connect physiology to bedside decision-making.

We start with absorption mechanics, which are more complex than simple passive diffusion. Modern research shows specific intestinal transporters—SR-BI, CD36, NPC1L1, and ABCA1—facilitate uptake of vitamins D, E, and K. Interestingly, vitamin A appears to lack a dedicated membrane transporter for dietary absorption. Absorption is also competitive: vitamins D, E, and K compete with one another, while vitamin A can suppress absorption of other fat-soluble vitamins without being affected itself. This interaction becomes clinically relevant in patients taking high-dose supplements.

Next we tackle vitamin A—vision, epithelial integrity, and immune defense.

Deficiency follows a classic progression:

Vitamin A also regulates epithelial differentiation and T-cell immune function, so deficiency increases susceptibility to infection. Even in high-income settings, restrictive diets or selective eating can lead to severe deficiency and permanent ocular injury.

Toxicity is equally important. Chronic hypervitaminosis A causes:

Sustained doses around 50,000 IU daily for >18 months can produce chronic toxicity.

We then shift to vitamin D—arguably the most clinically debated fat-soluble vitamin.

Vitamin D metabolism follows a three-step pathway:

UVB exposure converts 7-dehydrocholesterol in skin to vitamin D3

Hepatic conversion to 25-hydroxyvitamin D (calcidiol)

Renal activation to calcitriol (1,25-dihydroxyvitamin D)

This active hormone regulates calcium and phosphate homeostasis through tight feedback with parathyroid hormone.

Deficiency is widespread—over one billion people globally. Classic consequences include rickets in children and osteomalacia or osteoporosis in adults, but deficiency also contributes to proximal muscle weakness, increasing fall and fracture risk.

Vitamin D receptors are expressed throughout the body, and observational data link deficiency with cardiovascular disease, autoimmune disease, diabetes, multiple sclerosis, and cancer, although randomized trials show mixed results for extraskeletal benefits.

A key clinical debate remains optimal levels. Many experts advocate serum 25-hydroxyvitamin D concentrations above 40–50 ng/mL, often requiring supplementation beyond traditional recommendations.

Next up: vitamin E—the neurologic protector.

Deficiency primarily manifests with neurologic disease, including:

Severe cases can progress to blindness and dementia.

In cholestatic patients, interpretation requires nuance. Vitamin E levels may appear falsely normal due to hyperlipidemia, so clinicians should measure the vitamin E–to–total lipid ratio instead. Another diagnostic clue is red blood cell acanthocytosis on blood smear.

Toxicity is uncommon but high-dose vitamin E increases bleeding risk, particularly in patients taking anticoagulants.

We close with vitamin K—the coagulation vitamin with expanding roles in vascular biology.

Vitamin K enables γ-carboxylation of clotting factors II, VII, IX, and X and anticoagulant proteins C and S. Deficiency produces functional clotting factor impairment and bleeding once levels fall below ~30 U/dL.

In neonates, vitamin K deficiency bleeding (VKDB) occurs in three forms:

Routine intramuscular vitamin K prophylaxis at birth prevents nearly all cases of late VKDB.

Beyond coagulation, vitamin K activates matrix Gla protein, a powerful inhibitor of vascular calcification, and osteocalcin, which supports bone metabolism.

We also spotlight high-risk populations for fat-soluble vitamin deficiency, including patients with:

Certain medications impair absorption as well—orlistat, cholestyramine, and long-term antibiotics.

Finally, we review laboratory assessment strategies that actually work.

• Vitamin A: serum retinol 1–3 μmol/L normal

Bottom line: fat-soluble vitamins depend on lipid absorption, specialized transporters, and intact hepatobiliary and pancreatic function. Recognizing malabsorption states, neurologic or ocular clues, and appropriate biomarkers is essential to diagnosing deficiency early—before irreversible complications like blindness, neuropathy, fractures, or intracranial hemorrhage occur.

In this episode of Hospital Medicine Unplugged, we sprint through thalassemia—an inherited hemoglobinopathy defined by reduced or absent globin chain production, ineffective erythropoiesis, and chronic anemia. We break down the genetics, pathophysiology, clinical spectrum, and why this disorder remains the most common monogenic disease worldwide.

We start with the big picture. About 5% of the global population carries an α-thalassemia allele and 1.5% carries a β-thalassemia allele, with roughly 1.3 million people living with disease and ~40,000 affected infants born annually. The condition clusters across malaria-endemic regions—from sub-Saharan Africa and the Mediterranean to the Middle East, South Asia, and Southeast Asia—because the carrier state provides partial protection against malaria. Migration has increasingly brought thalassemia to North America and Europe, expanding its global clinical impact.

Next, we revisit normal hemoglobin physiology. Adult hemoglobin (HbA) is α₂β₂, with smaller fractions of HbA₂ (α₂δ₂) and HbF (α₂γ₂). During infancy, the body transitions from fetal hemoglobin to adult hemoglobin as γ-globin declines and β-globin production increases, regulated by transcription factors such as BCL11A and KLF1. Balanced α- and β-chain production is essential—when the balance breaks, unpaired globin chains accumulate, precipitate, and damage developing red cells, driving ineffective erythropoiesis.

We then dive into the genetic architecture.

• α-thalassemia is usually caused by gene deletions affecting HBA1 or HBA2.

Mutations are classified as:

Severity depends on genotype, but genetic modifiers matter—coinherited α-thalassemia, increased HbF production, or α-globin gene duplications can significantly alter disease expression.

Next, we map the clinical classification.

Alpha thalassemia spectrum:

Beta thalassemia spectrum:

Compound disorders add complexity, including HbE-β thalassemia and sickle-β thalassemia, where severity depends on the interacting mutations.

Then we unpack the pathophysiology driving complications.

Excess unpaired globin chains cause oxidative damage and premature death of erythroid precursors, leading to:

Chronic erythropoietin stimulation leads to skeletal deformities—frontal bossing, maxillary hypertrophy, and long-bone abnormalities.

Iron overload develops through two major pathways:

The downstream damage is systemic: cardiomyopathy, arrhythmias, liver fibrosis and cirrhosis, endocrine failure (growth delay, diabetes, hypothyroidism, hypoparathyroidism), osteoporosis, and thrombosis risk.

We close with the clinical spectrum.

• Trait: usually asymptomatic with incidental microcytosis

Bottom line: thalassemia is a disorder of globin chain imbalance leading to ineffective erythropoiesis, hemolysis, marrow expansion, and iron overload. Understanding the genetics, modifiers, and pathophysiology is essential to predicting severity, guiding transfusion strategies, and preventing the devastating end-organ complications of chronic iron toxicity.

In this episode of Hospital Medicine Unplugged, we sprint through ankylosing spondylitis and axial spondyloarthritis—recognize inflammatory back pain early, understand the disease spectrum from non-radiographic to radiographic disease, and treat aggressively to prevent structural damage and disability.

We begin with the modern concept of axial spondyloarthritis (axSpA), which represents a disease spectrum rather than a single condition. At one end is non-radiographic axial spondyloarthritis (nr-axSpA)—patients with typical symptoms but without definitive radiographic sacroiliitis. At the other end is radiographic axial spondyloarthritis (r-axSpA), historically known as ankylosing spondylitis, where structural changes in the sacroiliac joints are visible on X-ray.

Globally, axial spondyloarthritis affects roughly 0.3% to 1.4% of the population, with about 1% prevalence in the United States. Disease onset typically occurs early in life—more than 80% of patients develop symptoms before age 30. Radiographic disease is more common in men, while non-radiographic disease occurs equally in men and women.

A major challenge in this condition is diagnostic delay, which averages nearly seven years from symptom onset. This delay contributes to progressive inflammation, structural damage, and functional impairment before effective therapy is started.

The pathogenesis of axial spondyloarthritis involves a combination of genetic susceptibility, immune dysregulation, and environmental triggers. The strongest genetic risk factor is HLA-B27, present in 80–90% of patients with ankylosing spondylitis.

Several mechanisms have been proposed to explain how HLA-B27 contributes to disease:

• Presentation of arthritogenic peptides to CD8+ T cells

At the center of the inflammatory cascade lies the IL-23 / IL-17 axis, which drives activation of Th17 cells and production of pro-inflammatory cytokines including IL-17 and TNF-α. Mechanical stress at the entheses—the sites where ligaments and tendons attach to bone—triggers inflammation, making enthesitis the hallmark pathological process. Chronic inflammation eventually stimulates pathologic new bone formation, producing syndesmophytes and spinal ankylosis.

Clinically, the hallmark symptom is inflammatory back pain, present in more than 80% of patients. Key features include:

• Onset before age 45 years

Extra-articular manifestations are common and often provide diagnostic clues.

The most frequent is acute anterior uveitis, occurring in 25–30% of patients. Episodes typically present with sudden eye pain, redness, photophobia, and blurred vision.

Other associated conditions include:

• Inflammatory bowel disease (5–10%)

Because early disease may not show radiographic damage, classification relies on modern criteria.

The Modified New York Criteria require definite radiographic sacroiliitis and therefore identify only advanced disease.

In contrast, the ASAS classification criteria for axial spondyloarthritis allow earlier diagnosis. These criteria apply to patients with chronic back pain lasting ≥3 months with onset before age 45 and include two diagnostic pathways:

• Imaging arm: sacroiliitis on MRI or radiograph plus ≥1 SpA feature

These criteria have approximately 83% sensitivity and 84% specificity, enabling detection of earlier disease stages.

Monitoring disease activity is critical to guide treatment decisions. The Ankylosing Spondylitis Disease Activity Score (ASDAS) is the preferred measure because it incorporates both patient-reported symptoms and inflammatory markers such as CRP.

ASDAS categories include:

• Inactive disease: <1.3

Management begins with non-pharmacologic therapy, which remains foundational for all patients. This includes structured exercise programs, physical therapy, posture training, and smoking cessation, as smoking is associated with worse radiographic progression and poorer treatment response.

First-line pharmacologic therapy is NSAIDs, which reduce pain and inflammation. Continuous therapy may be more effective than intermittent use, although fewer than one quarter of patients achieve complete symptom control with NSAIDs alone.

For patients with persistent disease activity, biologic therapy is the next step.

TNF inhibitors were the first biologics proven effective, producing ASAS20 response rates of roughly 60% and reducing radiographic progression.

More recently, IL-17 inhibitors such as secukinumab and ixekizumab have shown comparable efficacy. A newer agent, bimekizumab, blocks both IL-17A and IL-17F, offering promising results.

JAK inhibitors, including upadacitinib and tofacitinib, provide an oral treatment option and demonstrate response rates exceeding 50%, though regulatory agencies caution about risks including cardiovascular events and infections.

Despite the strong genetic association with IL-23, IL-23 inhibitors have not demonstrated clinical benefit in axial spondyloarthritis, highlighting the complexity of immune signaling pathways.

Long-term outcomes vary widely. The strongest predictor of future structural damage is existing syndesmophytes at baseline. Other poor prognostic factors include male sex, smoking, early hip involvement, and persistent systemic inflammation.

Complications can also arise from the structural rigidity of the spine. Osteoporosis and vertebral fractures occur in up to 10% of patients, meaning new spinal pain—even after minor trauma—should prompt evaluation for fracture.

We close with the key clinical takeaways:

• Axial spondyloarthritis is a spectrum ranging from non-radiographic disease to classic ankylosing spondylitis

Early recognition and treatment are critical—because once structural ankylosis develops, damage is irreversible.

In this episode of Hospital Medicine Unplugged, we sprint through prosthetic heart valves—how to choose between mechanical and bioprosthetic valves, manage anticoagulation safely, recognize complications, and navigate the expanding role of transcatheter valve replacement.

We begin with the two major categories of prosthetic valves: mechanical valves and bioprosthetic (tissue) valves. Mechanical valves are constructed from durable materials such as pyrolytic carbon and are designed to last decades, but their thrombogenic surface requires lifelong anticoagulation with a vitamin K antagonist.

Anticoagulation targets depend on valve position and risk factors.

In most patients, low-dose aspirin (75–100 mg daily) is added to vitamin K antagonist therapy to further reduce thromboembolic risk.

Bioprosthetic valves, in contrast, are made from porcine valves or bovine pericardium. These valves are less thrombogenic, which allows for short-term anticoagulation (typically 3–6 months) after implantation followed by lifelong antiplatelet therapy with aspirin. The trade-off is durability—structural valve degeneration (SVD) eventually occurs due to calcification, fibrosis, or leaflet tearing.

Choosing between valve types requires balancing durability versus anticoagulation risk. Mechanical valves generally offer better long-term durability, while bioprosthetic valves avoid lifelong anticoagulation but may require future reoperation.

Age is one of the most important factors in valve selection. Evidence from large observational studies demonstrates that mechanical valves provide survival advantages in younger patients, particularly:

Current ACC/AHA guidelines generally recommend:

The treatment landscape has changed dramatically with the development of transcatheter aortic valve replacement (TAVR). Initially reserved for patients with prohibitive surgical risk, TAVR is now widely used across risk groups.

Landmark trials such as PARTNER 3 demonstrated that in low-risk patients with severe aortic stenosis, TAVR produced outcomes comparable to surgical valve replacement at five years. TAVR offers advantages including lower rates of atrial fibrillation and bleeding, though it carries higher risks of paravalvular regurgitation and pacemaker implantation.

Guidelines now recommend:

Anticoagulation management remains one of the most critical aspects of prosthetic valve care. Direct oral anticoagulants (DOACs are contraindicated in mechanical valves). The RE-ALIGN trial showed increased thromboembolic and bleeding complications with dabigatran compared with warfarin, leading to early termination of the study. More recently, the PROACT Xa trial evaluating apixaban in patients with On-X mechanical valves also demonstrated excess thromboembolic events.

For bioprosthetic valves, however, DOACs may be used in patients who develop atrial fibrillation, although long-term data remain limited.

Despite technological advances, prosthetic valves carry important complications. One of the most serious is prosthetic valve endocarditis (PVE), which is associated with high mortality. Management requires prolonged intravenous antibiotics, typically for at least six weeks, and surgery may be required for heart failure, uncontrolled infection, or large vegetations.

Another major complication is prosthetic valve thrombosis, particularly with mechanical valves. Management depends on clinical severity and thrombus size. Options include urgent surgery or low-dose, slow-infusion fibrinolysis, with modern thrombolytic protocols achieving over 90% success rates and low complication rates.

A subtler but clinically important issue is prosthesis–patient mismatch (PPM). This occurs when the effective orifice area of the prosthetic valve is too small relative to the patient’s body surface area, creating persistent obstruction despite valve replacement. Severe PPM is defined as indexed effective orifice area <0.65 cm²/m² and is associated with higher mortality, reduced left ventricular mass regression, and worse heart failure outcomes.

Certain populations require special consideration. Pregnancy with mechanical valves carries substantial maternal and fetal risk due to the competing challenges of anticoagulation and thrombosis prevention. Warfarin provides the most reliable valve protection but carries risk of embryopathy at higher doses. For women planning pregnancy, bioprosthetic valves are often preferred, even though they may require earlier replacement.

Finally, structural valve degeneration is the major limitation of bioprosthetic valves. The process occurs gradually and progresses through stages—from early structural changes without hemodynamic impact to severe valve dysfunction requiring reintervention. Risk factors for accelerated degeneration include younger age, renal disease, hypertension, hyperparathyroidism, and prosthesis–patient mismatch.

Because degeneration can occur silently, lifelong surveillance with periodic echocardiography is essential for all patients with prosthetic valves.

We close with the key clinical takeaways:

• Mechanical valves offer durability but require lifelong warfarin therapy

Prosthetic valve management is a lifelong process—successful outcomes depend not only on the procedure itself but on careful anticoagulation, surveillance, and early recognition of complications.

In this episode of Hospital Medicine Unplugged, we sprint through asbestosis—understand how inhaled fibers trigger progressive pulmonary fibrosis, recognize key radiographic features, and manage patients with attention to malignancy risk and progressive fibrotic disease.

We start with pathophysiology, where the story begins decades before symptoms appear. After inhalation, asbestos fibers deposit in the distal airways and alveoli. Alveolar macrophages attempt to engulf these fibers, but many fibers are too long to be fully internalized—triggering “frustrated phagocytosis.” This leads to persistent macrophage activation and release of inflammatory mediators including TNF-α, IL-1, and TGF-β. At the same time, reactive oxygen species form both from macrophage activation and from iron on the fiber surface, amplifying oxidative injury.

A key early event is alveolar epithelial cell apoptosis, driven by mitochondrial injury, p53-mediated pathways, and endoplasmic reticulum stress. Loss of epithelial integrity and chronic inflammation stimulate fibroblast activation and collagen deposition, ultimately producing the progressive interstitial fibrosis that defines asbestosis.

Not all asbestos fibers carry the same risk. Amphibole fibers—particularly crocidolite and amosite—are far more fibrogenic and carcinogenic than chrysotile fibers. Their needle-like shape, durability, and resistance to biological clearance allow them to persist in lung tissue for decades. Fiber dimensions matter: long fibers (>10–20 μm) and extremely thin fibers (<0.25 μm) pose the highest disease risk because they reach distal lung regions and resist macrophage clearance.

One of the defining features of asbestos disease is extraordinary latency. Clinical asbestosis usually develops 20–40 years after the first exposure, with peak disease occurrence around 40–45 years after exposure begins. Lung cancer tends to occur earlier, typically 30–35 years after exposure. Disease progression varies—some patients remain stable while others develop progressive fibrotic lung disease with significant annual declines in FVC, particularly those with fibrotic patterns on HRCT.

Diagnosis relies on a combination of exposure history, latency, imaging, and pulmonary function testing. According to consensus guidelines, the diagnosis requires:

• Documented asbestos exposure

While chest X-ray can detect classic small irregular opacities, high-resolution CT is far more sensitive. Key HRCT findings include:

• Subpleural curvilinear lines (one of the most specific findings)

Importantly, most patients with asbestosis also show benign pleural abnormalities, such as pleural plaques or diaphragmatic pleural thickening, which strongly support asbestos exposure.

Unfortunately, no disease-modifying therapies are currently approved specifically for asbestosis. Management traditionally focuses on supportive care, including:

• Smoking cessation

However, the treatment landscape is evolving. Because asbestosis can behave like other progressive fibrosing interstitial lung diseases, antifibrotic therapies are increasingly considered for patients with progressive disease. Nintedanib, approved for progressive fibrosing ILD, may slow lung function decline in patients with progressive asbestosis. Early studies of pirfenidone suggest acceptable safety and potential benefit, though definitive evidence remains limited.

Another critical dimension of asbestos exposure is malignancy risk. Asbestos causes two to six times more lung cancers than mesotheliomas, making asbestos-related lung cancer a major public health burden. The interaction with smoking is particularly dangerous: asbestos and smoking have a synergistic effect on lung cancer risk. In exposed workers, the combined effect can increase lung cancer mortality more than 30-fold.

Importantly, asbestos exposure increases lung cancer risk even in nonsmokers, but smoking cessation dramatically reduces risk over time. Within 10 years of quitting, lung cancer mortality drops significantly, and after 30 years, risk approaches that of never-smokers.

For malignant mesothelioma, amphibole fibers again carry the greatest risk. Crocidolite exposure has the highest potency, and mesothelioma risk continues to rise 40–50 years after initial exposure.

Because treatment options for mesothelioma remain limited, prevention and early detection are essential. The most effective intervention is elimination of exposure, enforced through occupational safety regulations, air monitoring, and protective equipment.

For individuals with significant asbestos exposure, low-dose CT screening can help detect early lung cancers, improving survival outcomes. Unfortunately, routine screening for mesothelioma is not currently recommended, as effective early detection strategies remain lacking.

We close with the key clinical takeaways:

• Asbestosis results from chronic macrophage activation and epithelial injury triggered by persistent asbestos fibers

Asbestosis remains a preventable occupational disease, but its long latency means clinicians continue to encounter its consequences decades after exposure—making exposure history, imaging recognition, and malignancy surveillance critical in modern clinical practice.

In this episode of Hospital Medicine Unplugged, we sprint through glomerulonephritis—recognize the nephritic syndrome, decode complement patterns and immunofluorescence clues, and manage diseases ranging from self-limited post-infectious GN to rapidly progressive crescentic disease.

We start with the clinical syndrome of glomerulonephritis, defined by glomerular inflammation producing hematuria, hypertension, edema, and reduced kidney function. The classic picture is nephritic syndrome—tea- or cola-colored urine, oliguria, periorbital edema, and elevated blood pressure. At the microscopic level, RBC casts are the pathognomonic finding, proving that bleeding originates from the glomerulus rather than the urinary tract.

Understanding disease requires revisiting the glomerular filtration barrier, composed of three layers: fenestrated endothelium, the glomerular basement membrane (GBM), and podocytes connected by slit diaphragms. This barrier normally filters plasma while retaining proteins. Podocytes are terminally differentiated and poorly regenerative, making them particularly vulnerable to immune-mediated injury.

The core pathophysiology of GN is immune-mediated inflammation. Antibodies, immune complexes, and complement activation trigger inflammatory cascades within the glomerulus. This leads to endocapillary proliferation, mesangial expansion, and leukocyte infiltration, narrowing capillary lumens and lowering GFR. Capillary wall damage allows red blood cells to leak into urine, while the sudden decline in filtration drives sodium and water retention, producing hypertension and edema.

Modern classification emphasizes pathogenesis rather than morphology, and most GN falls into five categories:

• Immune-complex GN – granular immunoglobulin deposition (post-infectious GN, IgA nephropathy, lupus nephritis, MPGN)

Epidemiology varies by disease. Post-streptococcal GN primarily affects children aged 2–10 years, particularly in developing regions. In contrast, IgA nephropathy is the most common primary glomerular disease worldwide and typically presents in young adults. Interestingly, epidemiology has shifted: childhood PSGN is declining, while adult infection-related GN—often associated with staphylococcal infections—is increasing.

Clinical presentation depends on the underlying disease. Post-streptococcal GN typically occurs 1–12 weeks after a streptococcal infection, producing abrupt edema, hypertension, and hematuria. IgA nephropathy, in contrast, often presents with synpharyngitic hematuria—visible hematuria occurring simultaneously with an upper respiratory infection.

The urinalysis is the diagnostic cornerstone. Key findings include dysmorphic red blood cells, RBC casts, and mild-to-moderate proteinuria. Complement levels help narrow the differential:

• Low C3 and low C4: lupus nephritis, cryoglobulinemia, immune-complex MPGN

A crucial teaching point: C3 should normalize within 6–8 weeks in post-streptococcal GN. Persistent hypocomplementemia suggests another diagnosis, such as lupus nephritis or MPGN.

Additional testing includes ASO titers and anti-DNase B antibodies for streptococcal infection, autoimmune markers such as ANA and ANCA, and viral testing for hepatitis B, hepatitis C, and HIV.

Imaging plays a limited role. Renal ultrasound typically shows normal or enlarged kidneys in acute GN, helping distinguish acute inflammatory disease from chronic kidney disease.

When the diagnosis remains unclear—or when disease is severe—a kidney biopsy is essential. Histology reveals characteristic patterns:

• Post-infectious GN: diffuse endocapillary proliferation with neutrophils

Immunofluorescence patterns guide classification:

• Granular deposition: immune-complex GN

Management begins with supportive care for all patients. Key interventions include:

• Blood pressure control, ideally ≤120/70 mmHg with ACE inhibitors or ARBs

Treatment then becomes etiology-specific.

For post-infectious GN, therapy is largely supportive because the disease usually resolves spontaneously. Edema typically improves within 1–2 weeks, and renal function normalizes within about 4 weeks.

IgA nephropathy, however, may progress. Treatment strategies now include:

• Targeted-release budesonide to reduce intestinal IgA production

In rapidly progressive (crescentic) GN, immediate therapy is essential. Treatment typically includes:

• High-dose glucocorticoids (IV methylprednisolone followed by oral prednisone)

For ANCA-associated vasculitis, rituximab is now equivalent to cyclophosphamide for induction therapy and may be superior in relapsing disease.

Prognosis varies widely. Post-streptococcal GN in children generally resolves completely, though subtle long-term kidney risk may remain. IgA nephropathy has a much more variable course, with up to half of patients progressing to kidney failure within 10 years.

Predictors of poor outcome include:

• Persistent hypertension

We close with the high-yield clinical pearls:

• RBC casts confirm glomerular bleeding

Glomerulonephritis is not a single disease but a spectrum of immune-mediated kidney disorders—and successful management depends on integrating clinical presentation, serology, complement levels, and biopsy findings to identify the exact mechanism driving glomerular injury.

In this episode of Hospital Medicine Unplugged, we sprint through thyroid cancer—understand the epidemiologic paradox of rising incidence but stable mortality, stage disease using modern AJCC criteria, apply ATA recurrence risk stratification, and tailor therapy from surgery and radioiodine to targeted molecular treatments.

We start with the epidemiology of thyroid carcinoma, the most common endocrine malignancy and the ninth most common cancer worldwide. In 2022 alone, there were roughly 821,000 new cases and 47,500 deaths globally. The disease shows a strong female predominance—about three quarters of cases occur in women, and the median age at diagnosis is in the early 50s. Notably, thyroid cancer is also the most common malignancy among adolescents and young adults aged 16–33 years.

One of the most striking trends is the dramatic rise in incidence over the past four decades. Global age-standardized incidence increased substantially from about 2.1 per 100,000 in 1990 to over 3.1 per 100,000 in 2017, with extremely high rates reported in countries such as South Korea, Cyprus, Ecuador, China, and Turkey. Yet mortality has remained remarkably stable at roughly 0.5 per 100,000, suggesting that much of the increase reflects overdiagnosis rather than a true surge in aggressive disease.

The driver behind this phenomenon is increased detection of small papillary thyroid cancers, often discovered incidentally during thyroid ultrasonography or cross-sectional imaging. Some studies estimate that more than 75% of thyroid cancers globally may represent overdiagnosis, particularly in high-income countries where imaging is widespread. Encouragingly, incidence rates have begun to plateau or decline in some regions following guideline changes discouraging unnecessary biopsy and treatment of very small nodules.

Next, we turn to staging, which guides prognosis and management. The AJCC 8th edition TNM staging system introduced an important shift by raising the prognostic age cutoff from 45 to 55 years. This reflects the excellent survival outcomes seen in younger patients.

For patients younger than 55 years, staging is remarkably simple:

This simplified system reflects the outstanding prognosis in younger individuals, with more than 98% survival regardless of tumor characteristics.

For patients 55 years and older, staging becomes more detailed and incorporates tumor size, lymph node involvement, and extrathyroidal extension. Importantly, the 8th edition refined the definition of extrathyroidal extension so that only gross invasion of strap muscles qualifies for T3b staging, which has downstaged many patients and improved prognostic accuracy.

However, staging alone does not fully predict recurrence. That role belongs to the American Thyroid Association (ATA) risk stratification system, which categorizes patients as low, intermediate, or high risk of recurrence.

Approximate recurrence rates are:

A key innovation in ATA management is dynamic risk stratification, where risk is continuously updated based on response to therapy.

Response categories include:

This dynamic approach allows clinicians to de-escalate surveillance and treatment for patients who demonstrate excellent responses over time.

At the molecular level, thyroid cancer has a remarkably simple genomic landscape, dominated by mutations activating the MAPK signaling pathway.

The most common driver mutation is BRAF V600E, found in about 60% of papillary thyroid cancers. This mutation is associated with classic and tall-cell variants, increased lymph node metastases, and reduced responsiveness to radioactive iodine due to suppression of the sodium-iodide symporter.

Another important group includes RAS mutations, seen in follicular thyroid cancers and follicular-variant papillary carcinomas. These tumors often demonstrate vascular invasion but retain better responsiveness to radioactive iodine therapy.

Chromosomal rearrangements also play a role. RET/PTC fusions are common in radiation-induced thyroid cancers and pediatric cases, while TERT promoter mutations—particularly when combined with BRAF mutations—are associated with aggressive disease and poor prognosis.

Management of differentiated thyroid cancer increasingly emphasizes risk-adapted therapy, particularly regarding radioactive iodine (RAI).

RAI can serve three purposes:

Modern guidelines recommend avoiding routine RAI in low-risk patients, particularly those with small intrathyroidal papillary cancers ≤2 cm, negative lymph nodes, low postoperative thyroglobulin, and normal ultrasound.

RAI becomes selectively recommended when additional risk factors are present, such as tumors >4 cm, nodal metastases, lymphatic invasion, aggressive histologic variants, or elevated postoperative thyroglobulin levels.

For high-risk disease, including gross extrathyroidal extension, extensive nodal disease, or distant metastases, RAI therapy remains standard because it improves both survival and recurrence outcomes.

When thyroid cancer becomes radioiodine-refractory, systemic therapy may be required. Several targeted agents are now available.

First-line multikinase inhibitors include:

Second-line therapy includes cabozantinib for patients progressing after first-line agents.

Precision medicine is increasingly important. Tumors with specific driver mutations may respond dramatically to targeted therapies:

• RET fusions: treated with selpercatinib or pralsetinib, with response rates approaching 80–90%

Despite these advances, systemic therapy is not curative and often causes substantial side effects. Therefore, treatment should generally be reserved for progressive or symptomatic disease, while patients with slow-growing, asymptomatic metastases may be safely observed.

We close with the key clinical takeaways:

• Rising thyroid cancer incidence largely reflects overdiagnosis of small papillary tumors

Thyroid cancer illustrates a modern shift in oncology—from one-size-fits-all treatment toward precision risk-adapted care, balancing effective therapy with avoidance of unnecessary intervention.

In this episode of Hospital Medicine Unplugged, we sprint through anaphylaxis—recognize the rapid systemic reaction, understand the mast-cell storm driving shock, and deliver epinephrine immediately to prevent cardiovascular collapse.

We begin with the definition and diagnostic framework. Anaphylaxis is a severe, rapid-onset, life-threatening systemic hypersensitivity reaction. When it progresses to circulatory collapse with profound vasodilation and vascular leak, it becomes anaphylactic shock, a form of distributive shock with relative hypovolemia. Modern guidelines define anaphylaxis clinically: acute onset of illness with skin or mucosal symptoms plus respiratory compromise, hypotension, or severe gastrointestinal symptoms, or hypotension/bronchospasm after known allergen exposure—even without skin findings.

Next comes epidemiology. Anaphylaxis occurs in roughly 50–112 episodes per 100,000 person-years, and 1.6–5.1% of adults in the United States experience an episode during their lifetime. Fortunately, modern treatment has kept mortality low. Case fatality rates among emergency presentations are about 0.25–0.33%, translating to roughly 186–225 deaths per year in the United States.

Triggers vary by age. Food-induced anaphylaxis predominates in young children, while medication-induced reactions are more common in adults, especially those over age 50.

At the core of anaphylaxis lies mast-cell and basophil activation. In classic IgE-mediated type I hypersensitivity, an allergen first sensitizes the immune system, leading B cells to produce IgE antibodies that bind to high-affinity FcεRI receptors on mast cells and basophils. On re-exposure, allergen cross-linking of IgE triggers rapid cellular degranulation.

This releases a cascade of mediators including:

• Histamine and tryptase

These mediators cause vasodilation, endothelial barrier disruption, bronchoconstriction, and massive capillary leak, shifting fluid from the intravascular space to tissues. The result is hypotension, airway compromise, and multisystem dysfunction.

Not all anaphylaxis is IgE mediated. Alternative mechanisms include IgG-mediated reactions, complement activation, contact system activation, and direct mast-cell activation via MRGPRX2 receptors. Clinically, these non-IgE pathways can produce identical presentations, which is why anaphylaxis remains a clinical diagnosis rather than a laboratory one.

The most common triggers fall into three major groups:

• Foods (≈32–37%)

In the United States, nine foods account for over 90% of IgE-mediated food allergies: milk, egg, wheat, soy, peanuts, tree nuts, fish, shellfish, and sesame. Peanuts remain the leading cause of fatal food-related anaphylaxis.

An emerging cause is alpha-gal syndrome, a delayed meat allergy triggered by tick bites, affecting tens to hundreds of thousands of individuals in the United States.

Medications are the most common trigger in adults, particularly beta-lactam antibiotics, followed by NSAIDs, biologic agents, chemotherapy drugs, and ACE inhibitors.

Another important concept is cofactors—conditions that lower the threshold for anaphylaxis. These include exercise, alcohol, infection, menstruation, and NSAID use. A classic example is food-dependent exercise-induced anaphylaxis, where patients tolerate a food normally but develop anaphylaxis if they exercise soon after ingestion.

Diagnosis relies on clinical criteria, most commonly the NIAID/FAAN criteria. Anaphylaxis is highly likely when there is acute involvement of skin or mucosa plus respiratory compromise or hypotension, multisystem involvement after allergen exposure, or isolated hypotension after exposure to a known trigger.

Laboratory confirmation is not required in the acute setting, but serum tryptase measured 90 minutes to 4 hours after symptom onset can support the diagnosis. An increase of 1.2 × baseline plus 2 ng/mL strongly suggests mast-cell activation.

Now to the most critical step: treatment.

Epinephrine is the first-line and life-saving therapy.

It should be administered immediately intramuscularly into the mid-anterolateral thigh at a dose of:

• 0.01 mg/kg of 1 mg/mL solution

Doses can be repeated every 5–15 minutes if symptoms persist. There are no contraindications to epinephrine in anaphylaxis—even in patients with cardiovascular disease.

Delayed epinephrine administration is the strongest modifiable risk factor for fatal anaphylaxis.

Adjunctive therapies follow epinephrine but never replace it. These include:

• High-flow oxygen

For patients taking beta-blockers who develop refractory hypotension, glucagon may be used because it increases cyclic AMP independent of beta receptors.

Rarely, patients develop refractory anaphylactic shock, defined by persistent symptoms despite multiple epinephrine doses. Management may require IV epinephrine infusion, additional vasopressors, airway management, and aggressive fluid resuscitation. In extreme cases, methylene blue or extracorporeal life support has been used as rescue therapy.

Another important phenomenon is biphasic anaphylaxis, where symptoms recur after initial resolution without new allergen exposure. This occurs in about 5–6% of cases, typically within 10 hours.

Recommended observation periods depend on severity:

• Minimum 4 hours for uncomplicated reactions

Longer monitoring is advised for patients with severe initial presentation, multiple epinephrine doses, asthma, unknown trigger, or prior biphasic reactions.

Special consideration is needed for patients on beta-blockers or ACE inhibitors, which may increase severity of reactions and blunt compensatory cardiovascular responses. These medications are not absolutely contraindicated, but management should involve shared decision-making regarding risks and benefits.

Long-term management focuses on prevention and preparedness.

All patients who experience anaphylaxis should receive:

• Epinephrine autoinjectors

Patients should carry two autoinjectors at all times, as repeat dosing may be required.

Additional prevention strategies include allergen avoidance, personalized emergency action plans, medical alert identification, and immunotherapy when appropriate. For example, venom immunotherapy is highly effective for Hymenoptera sting allergy, and oral immunotherapy is now available for peanut allergy.

We close with the key clinical pearls:

• Anaphylaxis is a clinical diagnosis—do not delay treatment

Recognize the signs, inject epinephrine early, and monitor carefully—because in anaphylaxis, minutes matter and rapid treatment saves lives.

In this episode of Hospital Medicine Unplugged, we sprint through upper motor neuron (UMN) syndromes—how spasticity develops, how to separate true reflex hyperexcitability from fixed stiffness, and how to diagnose and manage major UMN diseases like PLS and hereditary spastic paraplegia.

We begin with spasticity, a defining feature of UMN injury that is not simply an immediate “release phenomenon.” Its delayed appearance after stroke or spinal cord injury points to maladaptive plasticity in both the spinal cord and brain. The core problem is loss of descending inhibitory control, with reduced corticospinal input, increased reticulospinal drive, impaired spinal inhibitory circuits, heightened alpha motor neuron excitability, and reduced postactivation depression, especially with immobilization.

Clinically, spasticity is a velocity-dependent increase in tone caused by hyperexcitable stretch reflexes. But bedside hypertonia often has two components: reflex-mediated spasticity and intrinsic soft tissue stiffness from contracture and rheologic muscle change. That distinction matters. The Modified Ashworth Scale measures overall resistance, but the Tardieu Scale better separates dynamic spasticity from fixed mechanical tightness.

We then turn to primary lateral sclerosis (PLS), the prototypical adult UMN-predominant degenerative disorder. The 2020 consensus criteria define probable PLS as 2–4 years of progressive UMN syndrome and definite PLS as more than 4 years of symptoms. That time threshold matters because shorter duration carries higher risk of later ALS conversion. Even in clinically pure PLS, minor EMG abnormalities like fasciculations or fibrillations can occur, especially with longer disease duration.

Next is hereditary spastic paraplegia (HSP), a genetically diverse disorder marked by bilateral leg spasticity, hyperreflexia, and extensor plantar responses from length-dependent corticospinal tract degeneration. HSP is classified into pure forms, where spastic paraparesis dominates, and complex forms, where additional neurologic features appear. Although SPAST (SPG4) and SPG7 are among the most common mutations, a genetic diagnosis is still achieved in only a minority of patients.

MRI is the gold standard imaging study in suspected UMN disease. Key findings include corticospinal tract T2/FLAIR hyperintensity, especially in the posterior limb of the internal capsule and cerebral peduncles, as well as the “motor band sign,” a T2/SWI hypointensity in the precentral gyrus reflecting iron deposition. Motor cortex atrophy may be even more sensitive than the physical exam for detecting UMN degeneration and can appear before overt clinical signs.

We also highlight the distinction between pseudobulbar palsy and bulbar palsy. Pseudobulbar palsy comes from bilateral corticobulbar UMN lesions and produces spastic dysarthria, brisk jaw jerk, and exaggerated gag reflex. It is often accompanied by pseudobulbar affect—uncontrollable laughing or crying out of proportion to context. In contrast, bulbar palsy reflects LMN dysfunction of cranial nerve nuclei or nerves.

Management of spasticity follows a stepwise approach. Start with physical therapy, stretching, splinting, bracing, and positioning. For focal spasticity, botulinum toxin A has the strongest evidence and is preferred because it improves tone without systemic sedation. For generalized spasticity, oral agents include baclofen, tizanidine, benzodiazepines, and dantrolene, though benefit is often limited by sedation or weakness. In severe refractory cases, intrathecal baclofen pumps provide greater efficacy at lower doses—but pump failure can cause life-threatening withdrawal.

We close with the take-home moves: recognize that spasticity is dynamic neurophysiology plus biomechanics, use MRI and timeline to refine the diagnosis, distinguish pseudobulbar from bulbar syndromes, and treat spasticity with a layered rehab-first strategy before escalating to botulinum toxin or intrathecal therapy.

UMN syndromes are about more than “increased tone”—they are disorders of descending control, adaptive failure, and progressive disability, and careful phenotyping is what turns bedside findings into precise diagnosis and treatment.

In this episode of Hospital Medicine Unplugged, we break down endovascular infections—vascular graft infections, mycotic aneurysms, CIED infections, and septic thrombophlebitis syndromes—focusing on modern epidemiology, evolving microbiology, advanced imaging, and high-yield management strategies.

We begin with epidemiology clinicians should know. Vascular graft infections occur in ~0.5–6% of vascular reconstructions, while endovascular device infections occur in ~0.2–5% of procedures, with TEVAR carrying higher infection risk than abdominal repairs. Meanwhile, cardiac implantable electronic device (CIED) infections have increased substantially, reflecting growing device use.

Next we review key microbiology. Gram-positive cocci cause most vascular graft infections, with coagulase-negative staphylococci now more common than S. aureus. MRSA is increasingly prevalent and linked to worse outcomes, while Pseudomonas aeruginosa leads among gram-negative pathogens. For mycotic aneurysms, Salmonella species remain classic causes, with rare pathogens including Listeria and Mycobacterium tuberculosis.

We then highlight important clinical syndromes.

Diagnosis relies heavily on advanced imaging. CTA is typically the first-line test, while 18F-FDG PET/CT provides high sensitivity (~94%) and excellent negative predictive value, especially in late graft infections. TEE remains essential for suspected CIED infection, though repeat imaging may be needed if initial studies are negative.

Management requires combined antimicrobial and procedural strategies.

We close with key controversies and outcomes. Anticoagulation for septic thrombophlebitis remains debated, though many experts consider 6–12 weeks of therapy in selected patients. Despite advances, vascular graft infections and mycotic aneurysms carry high mortality—often exceeding 30% at one year—especially with MRSA.

Early recognition, PET/CT-guided diagnosis, aggressive antibiotics, and timely device removal remain the pillars of care for these complex infections.